Table 3.
Detailed results on biomarkers that are significantly differentially expressed in the pairwise comparisons. The differential expression is quantified by mean change in the biomarkers.
| Comparison | Biomarker | Mean Fluorescence Intensity (MFI) Difference (A) - (B) (95% CI) | Tukey Adjusted p-Value |
|---|---|---|---|
| RAP (N = 20) (A) vs. Controls (N= 41) (B) | |||
| IFNγ | −0.39 (−0.72 – −0.05) | 0.016 | |
| IL-13 | −0.37 (−0.72 – −0.02) | 0.037 | |
| IL-1β | −0.36 (−0.68 – −0.04) | 0.022 | |
| IL-27 | −0.38 (−0.71 – −0.04) | 0.020 | |
| IL-31 | −0.37 (−0.69 – −0.06) | 0.011 | |
| FASL | −0.37 (−0.73 – −0.01) | 0.043 | |
| CP (N=40) (A) vs. Controls (N=41) (B) | |||
| GM-CSF | −0.78 (−1.35 – −0.22) | 0.003 | |
| IFNβ | 0.60 (0.00 – 1.20) | 0.048 | |
| Leptin | −1.36 (−2.38 – −0.34) | 0.004 | |
| PDGFB | −0.58 (−1.08 – −0.08) | 0.017 | |
| Resistin | 0.90 (0.22 – 1.59) | 0.004 | |
| PDAC (N=78) (A) vs. Controls (N=41) (B) | |||
| GM-CSF | −0.73 (−1.22 – −0.24) | 0.001 | |
| IL-31 | −0.29 (−0.51 – −0.07) | 0.004 | |
| Leptin | −0.96 (−1.85 – −0.08) | 0.027 | |
| FASL | −0.30 (−0.56 – −0.04) | 0.015 | |
| CP (N=40) (A) vs. RAP (N=20) (B) | |||
| Resistin | 1.05 (0.21 – 1.90) | 0.007 | |
| SCF | 0.38 (0.03 – 0.73) | 0.027 | |
| MIP-1α | 0.66 (0.03 – 1.30) | 0.035 | |
| IL-17F | 0.50 (0.01 – 0.99) | 0.045 | |
| PDAC (N=78) (A) vs. RAP (N=20) (B) | |||
| HGF | 0.45 (0.07 – 0.83) | 0.014 | |
| SCF | 0.36 (0.04 – 0.68) | 0.019 | |
| IL-12P40 | 0.49 (0.06 – 0.91) | 0.017 | |
| MIG | 0.54 (0.09 – 0.99) | 0.012 | |
| TNFα | 0.19 (0.01 – 0.38) | 0.032 | |
| PDAC (N=78) (A) vs CP (N=40) (B) | |||
| IFNβ | −0.54 (−1.06 – −0.02) | 0.040 | |
| IL-17F | −0.39 (−0.74 – −0.04) | 0.023 | |
| PDGFB | 0.46 (0.02 – 0.90) | 0.036 | |
| Disease Subgroup Analysis | |||
| Controls with DM (N=20) (A) vs. Controls without DM (N=21) (B) | |||
| IL-1α | −0.57 (−0.92 – −0.21) | 0.003 | |
| SDF1A | −0.46 (−0.75 – −0.16) | 0.003 | |
| Resistin | −0.82 (−1.36 – −0.27) | 0.004 | |
| VEGF | −0.47 (−0.81 – −0.12) | 0.009 | |
| DM Subgroup Analysis | |||
| CP with DM (N=20) (A) vs. DM Controls (N=20) (B) | |||
| GM-CSF | −0.91 (−1.63 – −0.17) | 0.012 | |
| Resistin | 1.39 (0.50 – 2.29) | 0.001 | |
| IL-1α | 0.56 (0.07 – 1.06) | 0.020 | |
| RANTES | 0.61 (0.16 – 1.06) | 0.005 | |
| SDF1A | 0.50 (0.05 – 0.94) | 0.027 | |
| PDAC with DM (N=20) (A) vs. DM Controls (N=20) (B) | |||
| GM-CSF | −0.83 (−1.43 – −0.22) | 0.004 | |
| IL-31 | −0.34 (−0.60 – −0.08) | 0.007 | |
| FASL | −0.33 (−0.63 – −0.04) | 0.022 | |
| RANTES | 0.50 (0.13 – 0.87) | 0.005 | |
| Resistin | 0.79 (0.06 – 1.53) | 0.031 | |
| ICAM1 | 0.70 (0.07 – 1.33) | 0.027 | |
| PDAC with DM (N=20) (A) vs. CP with DM (N=20) (B) | |||
| PDGFB | 0.57 (0.05 – 1.09) | 0.026 |